Warning Letter — Umendra Life Sciences Private Limited
The FDA issued a Warning Letter to Umendra Life Sciences Private Limited following an assessment by the Center for Drug Evaluation and Research (CDER).
This affects Umendra Life Sciences Private Limited, specifically its drug manufacturing operations and associated quality and regulatory departments.
While the specific violations are not detailed in the brief excerpt, the issuance of a Warning Letter by CDER indicates significant deviations from regulatory standards. This may lead to import alerts or the withholding of drug product approvals if the cited deficiencies are not remediated to the agency's satisfaction.
Regulatory and QA teams should ensure that all foreign manufacturing sites are prepared for potential FDA inspections and that quality management systems are robust enough to meet CDER standards. Firms should conduct internal audits to verify compliance with current Good Manufacturing Practices (cGMP).
FDA Warning Letter issued to: Umendra Life Sciences Private Limited. 06/02/2026 — Center for Drug Evaluation and Research (CDER). Source: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/umendra-life-sciences-private-limited-721752-06022026
Open in openFDA / FDA.gov